South Korea · Delayed Price · Currency is KRW KBIO LABS Statistics
Total Valuation
KBIO LABS has a market cap or net worth of KRW 25.82 billion. The enterprise value is 34.30 billion.
| Market Cap | 25.82B |
| Enterprise Value | 34.30B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KBIO LABS has 25.85 million shares outstanding. The number of shares has increased by 0.12% in one year.
| Current Share Class | 25.85M |
| Shares Outstanding | 25.85M |
| Shares Change (YoY) | +0.12% |
| Shares Change (QoQ) | -0.23% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 23.72M |
Valuation Ratios
The trailing PE ratio is 0.99.
| PE Ratio | 0.99 |
| Forward PE | n/a |
| PS Ratio | 0.28 |
| PB Ratio | 0.41 |
| P/TBV Ratio | 0.65 |
| P/FCF Ratio | 4.93 |
| P/OCF Ratio | 4.91 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.32, with an EV/FCF ratio of 6.55.
| EV / Earnings | n/a |
| EV / Sales | 0.37 |
| EV / EBITDA | 14.32 |
| EV / EBIT | 24.22 |
| EV / FCF | 6.55 |
Financial Position
The company has a current ratio of 2.38, with a Debt / Equity ratio of 0.00.
| Current Ratio | 2.38 |
| Quick Ratio | 1.87 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.12 |
| Debt / FCF | 0.06 |
| Interest Coverage | 28.70 |
Financial Efficiency
Return on equity (ROE) is -4.12% and return on invested capital (ROIC) is 3.18%.
| Return on Equity (ROE) | -4.12% |
| Return on Assets (ROA) | 0.94% |
| Return on Invested Capital (ROIC) | 3.18% |
| Return on Capital Employed (ROCE) | 2.22% |
| Weighted Average Cost of Capital (WACC) | 9.10% |
| Revenue Per Employee | 2.42B |
| Profits Per Employee | -391.65M |
| Employee Count | 38 |
| Asset Turnover | 0.98 |
| Inventory Turnover | 19.67 |
Taxes
In the past 12 months, KBIO LABS has paid 162.07 million in taxes.
| Income Tax | 162.07M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.87% in the last 52 weeks. The beta is 0.87, so KBIO LABS's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | -27.87% |
| 50-Day Moving Average | 900.34 |
| 200-Day Moving Average | 1,264.44 |
| Relative Strength Index (RSI) | 53.03 |
| Average Volume (20 Days) | 157,754 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KBIO LABS had revenue of KRW 92.08 billion and -14.88 billion in losses. Loss per share was -645.34.
| Revenue | 92.08B |
| Gross Profit | 13.31B |
| Operating Income | 1.42B |
| Pretax Income | -3.29B |
| Net Income | -14.88B |
| EBITDA | 2.40B |
| EBIT | 1.42B |
| Loss Per Share | -645.34 |
Balance Sheet
The company has 15.08 billion in cash and 298.03 million in debt, with a net cash position of 14.79 billion or 572.07 per share.
| Cash & Cash Equivalents | 15.08B |
| Total Debt | 298.03M |
| Net Cash | 14.79B |
| Net Cash Per Share | 572.07 |
| Equity (Book Value) | 63.19B |
| Book Value Per Share | 1,728.20 |
| Working Capital | 14.71B |
Cash Flow
In the last 12 months, operating cash flow was 5.26 billion and capital expenditures -25.02 million, giving a free cash flow of 5.24 billion.
| Operating Cash Flow | 5.26B |
| Capital Expenditures | -25.02M |
| Depreciation & Amortization | 979.66M |
| Net Borrowing | -799.90M |
| Free Cash Flow | 5.24B |
| FCF Per Share | 202.59 |
Margins
Gross margin is 14.46%, with operating and profit margins of 1.54% and -16.16%.
| Gross Margin | 14.46% |
| Operating Margin | 1.54% |
| Pretax Margin | -3.58% |
| Profit Margin | -16.16% |
| EBITDA Margin | 2.60% |
| EBIT Margin | 1.54% |
| FCF Margin | 5.69% |
Dividends & Yields
KBIO LABS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.12% |
| Shareholder Yield | -0.12% |
| Earnings Yield | -57.64% |
| FCF Yield | 20.28% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 14, 2026. It was a reverse split with a ratio of 0.2.
| Last Split Date | Apr 14, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
KBIO LABS has an Altman Z-Score of 1.98 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.98 |
| Piotroski F-Score | 4 |